US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,364.65

+12.380.92%

Number of Gainers:10

Number of Losers:7

Number of Flat:3

PE:- -

High:1,374.85

Open:1,352.30

Low:1,342.81

Close:1,352.26

Loading ...

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

ACCESS Newswire

3 of Wall Street’s Favorite Stocks Walking a Fine Line

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

AstraZeneca CEO Urges Europe to Spend More on Health or Risk Falling Behind -- Market Talk

Novavax Says COVID Vaccine Application 'Approvable'

MT Newswires Live

FDA Asks Novavax for Commitment on Post-Approval Studies for COVID Vaccine

BUZZ-Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks

Novavax Shares up 13.8% Premarket After Co Says Covid-19 Vaccine Is Approvable Based on Conversations With the US FDA

THOMSON REUTERS

BRIEF-Novavax Inc To Engage With FDA To Address Pmc Request

Novavax Inc - to Engage With FDA to Address Pmc Request - SEC Filing

THOMSON REUTERS

Novavax Inc - FDA Requests Post Marketing Commitment for Additional Clinical Data for Its Covid-19 Vaccine

THOMSON REUTERS

Novavax: "We Believe That Our Bla Is Approvable Based on Conversations With FDA, as of Our Pdufa Date on April 1 and Through Today"

THOMSON REUTERS

Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure

Cautious Outlook: Moderna’s Revenue and EPS Projections Lead to Hold Rating and Lowered Price Target

European pharma companies push for higher drug prices in EU amid U.S. tariff threats

Warburg Research Sticks to Their Buy Rating for Commerzbank (0RLW)

Warburg Research Remains a Buy on SAP SE (0NW4)

Promising Commercial Potential for Gilead’s Trodelvy Following Successful ASCENT-04 Trial

Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1364.6454,"timestamp":1745956799999,"preClose":1352.2611,"halted":0,"volume":158308438,"delay":0,"changeRate":0.009158,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":12.384277,"latestTime":"04-29 16:00:00 EDT","open":1352.2991,"high":1374.8529,"low":1342.8104,"amount":5426931590.916596,"amplitude":0.023695,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745971200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.606724,"peRate":21.80267,"turnoverRate":0.010209,"increases":10,"decrements":7,"flats":3,"marketCap":1127156925047,"floatMarketCap":1107301514087},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1374.8529,"amplitude":0.023695,"preClose":1352.2611,"low":1342.8104,"pbRate":"3.606724","latestPrice":1364.6454,"volume":158308438,"delay":0,"open":1352.2991,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1350.4775,"twentyDayClose":1427.887,"sixtyDayClose":1356.0358,"secType":"PLATE","market":"US","turnoverRate":0.010209,"peRate":21.80267,"marketCap":1127156925047,"floatMarketCap":1107301514087,"timestamp":1745956799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":7,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529868706","title":"Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2529868706","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529868706?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:10","pubTimestamp":1745413800,"startTime":"0","endTime":"0","summary":"Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry. Lexaria's technology could enhance performance and lower side effects. By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug.Eli Lilly plans to apply for approval to launch the drug for both weight loss and diabetes treatment in 2026 - and that rapid path to market, combined with the fact that it might be only the 2nd oral GLP-1 drug to potentially be approved by the Food and Drug Administration , is likely responsible for the dramatic market response to the news.Although clearly a positive step forward for the weight loss and diabetes treatment sectors, it should still be noted that 13% to 18% of patients receiving the drug ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recent-glp-1-industry-developments-131000677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","BK4144","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","GLP","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4590","BK4592","LU0306806265.USD","IE00B19Z3581.USD","LEXXW","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LEXX","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2529682525","title":"3 of Wall Street’s Favorite Stocks Walking a Fine Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682525","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682525?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:04","pubTimestamp":1745413440,"startTime":"0","endTime":"0","summary":"Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.Specializing in digital casino gaming, Inspired  is a provider of gaming hardware, virtual sports platforms, and server-based gaming systems.Annual revenue growth of 3.1% over the last two years was below our standards for the consumer discretionary sector. Anticipated sales growth of 2.2% for the next year implies demand will be shaky. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital. Pfizer ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-wall-street-favorite-stocks-130400724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225771236.USD","LU0321505439.SGD","SG9999002232.USD","BK4568","BK4581","BK4216","BK4007","LU1894683264.USD","LU0122379950.USD","LU1883839398.USD","SG9999001176.USD","LU0306807586.USD","SG9999001176.SGD","INSE","SGXZ57979304.SGD","BK4534","BK4588","LU0234572021.USD","PFE","BK4550","LU0170899867.USD","SG9999003800.SGD","LU0058720904.USD","LU0289739699.SGD","SG9999013999.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4585","SG9999011175.SGD","LU0306806265.USD","LU1066051498.USD","LU1894683348.USD","LU0321505868.SGD","LU0225284248.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE0002270589.USD","SG9999002224.SGD","LU0868494617.USD","BK4599","MTN","LU0456855351.SGD","LU0985481810.HKD","LU1057294990.SGD","BK4150","IE00BLSP4452.SGD","BK4592"],"gpt_icon":1},{"id":"2529625636","title":"GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529625636","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529625636?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:00","pubTimestamp":1745413200,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - April 23, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-report-first-quarter-2025-130000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4568","BK4535","R","BK4139","BNTX","BK4022","BK4588","GOVX","BK4232","BK4585","GOVXW","BK4548","BK4551"],"gpt_icon":0},{"id":"2529268811","title":"AstraZeneca CEO Urges Europe to Spend More on Health or Risk Falling Behind -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2529268811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529268811?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:57","pubTimestamp":1745413020,"startTime":"0","endTime":"0","summary":"1256 GMT - AstraZeneca's Chief Executive officer Pascal Soriot says Europe must boost investment into healthcare, as it has done with defense spending, amid what he calls a shifting world order. \"Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk,\" Soriot says. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","LU2456880835.USD","SNY","LU0070302665.USD","IE0002141913.USD","BK4578","BK4568","LU2417539215.USD","LU0889565916.HKD","NVS","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","BK4532","IE0009355771.USD","IE00BFXG1179.USD","LU1829250122.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0320765489.SGD","LU0208291251.USD","LU0109394709.USD","BK4007","BK4588","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2529688883","title":"Novavax Says COVID Vaccine Application 'Approvable'","url":"https://stock-news.laohu8.com/highlight/detail?id=2529688883","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529688883?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:45","pubTimestamp":1745412308,"startTime":"0","endTime":"0","summary":"Novavax  said Wednesday it believes its biologics license application for its COVID-19 vaccine is \"approvable\" by the US Food and Drug Administration based on ongoing discussions.The company said the FDA recently asked for a post-marketing commitment to collect additional clinical data.Novavax said it will work quickly to comply with the request and obtain final approval.Shares of Novavax rose 12% in recent premarket activity Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4547","BK4585","BK4568","NVAX","BK4588"],"gpt_icon":0},{"id":"2529050762","title":"FDA Asks Novavax for Commitment on Post-Approval Studies for COVID Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2529050762","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529050762?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:33","pubTimestamp":1745411602,"startTime":"0","endTime":"0","summary":"UPDATE 1-FDA asks Novavax for commitment on post-approval studies for COVID vaccineAdds shares in paragraph 2, details in paragraphs 3,4 and 5April 23  - Novavax NVAX.O said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.Shares of the biotech rose 12% to $7.07 in premarket trading. The FDA had missed its deadline for making a decision on traditional approval for the company's protein-based shot earlier this month. Novavax said it believes that the company's marketing application is \"approvable\" based on its conversations with the FDA.   ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R117S:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","BK4547","BK4568","NVAX"],"gpt_icon":1},{"id":"2529077995","title":"BUZZ-Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2529077995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529077995?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:28","pubTimestamp":1745411295,"startTime":"0","endTime":"0","summary":"BUZZ-Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks**  Shares of vaccine maker Novavax NVAX.O rise  13% to $7.06 premarket** Co says its COVID-19 vaccine is \"approvable based on conversations with the U.S. Food and Drug Administration \"** NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval**  The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month** Up to last close, stock had fallen 22.3% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL6N3R10JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4568","BK4547","NVAX","BK4139"],"gpt_icon":0},{"id":"2529502910","title":"Novavax Shares up 13.8% Premarket After Co Says Covid-19 Vaccine Is Approvable Based on Conversations With the US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529502910?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:12","pubTimestamp":1745410363,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R10YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","BK4568","BK4585","BK4547","NVAX"],"gpt_icon":0},{"id":"2529067504","title":"BRIEF-Novavax Inc To Engage With FDA To Address Pmc Request","url":"https://stock-news.laohu8.com/highlight/detail?id=2529067504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529067504?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:03","pubTimestamp":1745409807,"startTime":"0","endTime":"0","summary":"BRIEF-Novavax Inc To Engage With FDA To Address Pmc RequestApril 23  - Novavax Inc NVAX.O:NOVAVAX INC - TO ENGAGE WITH FDA TO ADDRESS PMC REQUEST - SEC FILINGNOVAVAX: \"WE BELIEVE THAT OUR BLA IS APPROVABLE BASED ON CONVERSATIONS WITH FDA, AS OF OUR PDUFA DATE ON APRIL 1 AND THROUGH TODAY\"NOVAVAX INC - FDA REQUESTS POST MARKETING COMMITMENT FOR ADDITIONAL CLINICAL DATA FOR ITS COVID-19 VACCINEFurther company coverage: NVAX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R1193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4568","BK4547","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2529850408","title":"Novavax Inc - to Engage With FDA to Address Pmc Request - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529850408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529850408?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:02","pubTimestamp":1745409724,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R1193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4585","BK4568","BK4588","BK4139","NVAX"],"gpt_icon":0},{"id":"2529706504","title":"Novavax Inc - FDA Requests Post Marketing Commitment for Additional Clinical Data for Its Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2529706504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529706504?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:02","pubTimestamp":1745409724,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R1193:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4547","NVAX","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2529504083","title":"Novavax: \"We Believe That Our Bla Is Approvable Based on Conversations With FDA, as of Our Pdufa Date on April 1 and Through Today\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2529504083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529504083?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:02","pubTimestamp":1745409724,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R1193:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","BK4585","NVAX","BK4547","BK4588"],"gpt_icon":0},{"id":"2529138507","title":"Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2529138507","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529138507?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"Initial Clinical Studies Completed with Significant Positive Results. The Cleveland Clinic Foundation, Abbott Laboratories and a New Era Associates  fund to Acquire Economic Interests in VTAK. Cardionomic was a venture capital and strategic investor-funded privately held company backed by the Cleveland Clinic Foundation, Abbott Laboratories and New Enterprise Associates  that had been developing for a number of years a new therapy based upon novel technology for the treatment of acute decompensated heart failure, or ADHF, for which over 1 million Americans are hospitalized annually. Patients admitted for ADHF have high in-hospital morbidity, frequent rehospitalization and subsequent death. The CPNS System consists of electrical stimulation via a temporary catheter inserted in the pulmonary artery targeting the root cause of heart failure by stimulating the autonomic cardiac nerves to restore autonomic balance. The initial target patient population for the therapy is hospitalized ADHF p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catheter-precision-acquire-assets-development-120000911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VTAK","LU2237957811.SGD","CPNS","LU2237957902.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1989763427.SGD","SSI","IE00B4R5TH58.HKD","LU0266013472.USD","LU1721429402.USD","IE0009355771.USD","LU0122379950.USD","LU2133065610.SGD","BK4581","BK4585","LU1914381329.SGD","LU0234572021.USD","LU2468319806.SGD","SG9999002232.USD","SG9999004303.SGD","LU1989763690.USD","IE00BJT1NW94.SGD","BK4588","BK4568","LU1061106388.HKD","BK4592","ABT","BK4566","IE0002141913.USD","LU1721429741.USD","LU2112291526.USD","NEA","SGXZ23171101.USD","BK4082","LU1691799644.USD","SG9999002224.SGD","LU0868494617.USD","LU0170899867.USD","BK4504","LU1057294990.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4533","LU2089984988.USD"],"gpt_icon":0},{"id":"2529250309","title":"Cautious Outlook: Moderna’s Revenue and EPS Projections Lead to Hold Rating and Lowered Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2529250309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529250309?lang=en_us&edition=fundamental","pubTime":"2025-04-23 18:46","pubTimestamp":1745405178,"startTime":"0","endTime":"0","summary":"Analyst Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $30.00 from $3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-outlook-modernas-revenue-and-eps-projections-lead-to-hold-rating-and-lowered-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-outlook-modernas-revenue-and-eps-projections-lead-to-hold-rating-and-lowered-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4501","BK4568","BK4585","BK4139","BK4532","BK4548","BK4588","BK4533","BK4534","MRNA"],"gpt_icon":0},{"id":"2529560572","title":"European pharma companies push for higher drug prices in EU amid U.S. tariff threats","url":"https://stock-news.laohu8.com/highlight/detail?id=2529560572","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529560572?lang=en_us&edition=fundamental","pubTime":"2025-04-23 18:18","pubTimestamp":1745403497,"startTime":"0","endTime":"0","summary":"UPDATE 2-European pharma companies push for higher drug prices in EU amid U.S. tariff threatsSanofi, Novartis CEOs urge EU list price closer to US net levelsComes after EU pharma warn tariffs could expedite shift to USUS pays nearly three times more than developed nations for drugsAstraZeneca says Europe must protect its health sovereigntyAdds AstraZeneca CEO comments in paragraphs 2-3, European Commission comments in paragraph 10By Maggie Fick. \"Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk,\" Soriot said in a statement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL1N3R10B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1804176565.USD","LU0784385840.USD","IE0002270589.USD","BK4568","LU0823416689.USD","LU1261432733.SGD","LU1119994496.HKD","LU1267930490.SGD","LU0098860793.USD","SGXZ81514606.USD","LU0158827948.USD","SG9999001176.USD","LU1481600234.SGD","LU0203202063.USD","LU1989771016.USD","LU2211815571.USD","LU1066053197.SGD","IE00B42XCP33.USD","AZN.UK","03165","LU1267930573.SGD","LU0708994859.HKD","LU0203347892.USD","LU2089283258.USD","LU2360106947.USD","LU2264538146.SGD","LU0757432116.USD","LU1551013425.SGD","LU1221951129.SGD","LU1712237335.SGD","LU0456855351.SGD","LU1430594728.SGD","JNJ","LU0471298694.HKD","LU2505996509.AUD","LU2471134879.HKD","BK4599","LU1585245621.USD","LU2279689827.SGD","LU2089984988.USD","LU0047473722.EUR","LU0079474960.USD","LU1267930730.SGD","LU1935042991.SGD","SG9999001176.SGD","LU1023059063.AUD","LU1880407132.USD","LU2237443549.SGD","LU0792757196.USD"],"gpt_icon":1},{"id":"2529573047","title":"Warburg Research Sticks to Their Buy Rating for Commerzbank (0RLW)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529573047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529573047?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:38","pubTimestamp":1745401108,"startTime":"0","endTime":"0","summary":"In a report released today, Andreas Plaesier from Warburg Research maintained a Buy rating on Commerzbank (0RLW – Research Report), with a price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/warburg-research-sticks-to-their-buy-rating-for-commerzbank-0rlw-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/warburg-research-sticks-to-their-buy-rating-for-commerzbank-0rlw-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4568","BK4551","BK4588","BNTX","BK4535","BK4139","BK4548"],"gpt_icon":0},{"id":"2529573718","title":"Warburg Research Remains a Buy on SAP SE (0NW4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529573718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529573718?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:38","pubTimestamp":1745401084,"startTime":"0","endTime":"0","summary":"Warburg Research analyst Andreas Wolf maintained a Buy rating on SAP SE (0NW4 – Research Report) today and set a price target of €275.00. The compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/warburg-research-remains-a-buy-on-sap-se-0nw4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/warburg-research-remains-a-buy-on-sap-se-0nw4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4585","BK4535","BK4139","BK4548","BK4588","BK4551","BNTX"],"gpt_icon":0},{"id":"2529411395","title":"Promising Commercial Potential for Gilead’s Trodelvy Following Successful ASCENT-04 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529411395","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529411395?lang=en_us&edition=fundamental","pubTime":"2025-04-23 14:36","pubTimestamp":1745390177,"startTime":"0","endTime":"0","summary":"Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Gilead Sciences (GILD – Research Report), boosting the price target to $115....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-commercial-potential-for-gileads-trodelvy-following-successful-ascent-04-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-commercial-potential-for-gileads-trodelvy-following-successful-ascent-04-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089984988.USD","LU1585245621.USD","BK4578","LU1066051498.USD","IE00B3T34201.USD","BK4139","BK4588","LU0320765992.SGD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU1839511570.USD","IE0002270589.USD","LU2087621335.USD","LU1430594728.SGD","BK4568","IE00B19Z3B42.SGD","LU0234570918.USD","GILD","LU2468319806.SGD","IE00B19Z3581.USD","BK4585","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4550","LU0109394709.USD","IE00BKVL7J92.USD","BK4532","LU1571399168.USD","LU0889565916.HKD","BK4566","BK4583","LU0289739699.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2529562205","title":"Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529562205","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529562205?lang=en_us&edition=fundamental","pubTime":"2025-04-23 06:47","pubTimestamp":1745362061,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Multibagger Penny Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Corvus Pharmaceuticals, Inc.  stands against other best multibagger penny stocks to buy according to billionaires.Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars. Given that some cost as little as $2, they can be tempting for growing money quickly without spending much. While it’s possible to achieve significant returns while investing in companies with depressed stock prices, caution is always of utmost importance.For this article, we used a stock screener first to identify stocks priced under $5 that have posted huge gains over the past year . From the obtained dataset, we selected penny stocks with the highest percentage gains in stock performance over the past year . The list is ranked based on the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corvus-pharmaceuticals-inc-crvs-best-224741847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","NQmain","TSYW.SI","PSQ","TQQQ","USAW.SI","BK4139","BK4568","SQQQ","CRVS",".IXIC","MNQmain","QID","QLD","USJW.SI"],"gpt_icon":1},{"id":"2529567450","title":"Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2529567450","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529567450?lang=en_us&edition=fundamental","pubTime":"2025-04-23 06:15","pubTimestamp":1745360115,"startTime":"0","endTime":"0","summary":"The most recent trading session ended with Astrazeneca  standing at $67.87, reflecting a +1.45% shift from the previouse trading day's closing. This change lagged the S&P 500's 2.51% gain on the day. Meanwhile, the Dow experienced a rise of 2.66%, and the technology-dominated Nasdaq saw an increase of 2.71%.Coming into today, shares of the pharmaceutical had lost 9.7% in the past month. In that same time, the Medical sector lost 11.09%, while the S&P 500 lost 8.86%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on April 29, 2025. The company is expected to report EPS of $1.10, up 6.8% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $13.68 billion, reflecting a 7.88% rise from the equivalent quarter last year.The Zacks Industry Rank gauges the strength of our industry groups by measuring the averag","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-azn-rises-trails-market-221515930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ISBC","LU1829250122.USD","BK4568","LU2462157665.USD","LU2417539215.USD","LU2456880835.USD","LU0889565916.HKD","LU0320765992.SGD","BK4585","LU0109394709.USD","BK4007","BK4211","BK4588","AZN","LU2236285917.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":10,"totalSize":308,"code":"91000000","status":"200"}]}}